1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Panacea Biotec Limited

Panacea Biotec Limited

311.45
INR
-15.35
(-4.70%)
-1.44EPS
34.66BMarket Cap
Panacea Biotec Limited
NSE:PANACEABIO
(National Stock Exchange of India)

Recent

price

311.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
184.67
115.93
99.34
83.26
112.19
106.62
85.77
93.6
73.85
87.7
100.84
107.63
74.6
90.11
80.42
99.59
108.46
Revenue per Share
22.87
-33.58
-38.25
-18.31
-17.39
-2.99
-9.18
-12.08
6.16
-31.72
-24.11
176.05
-5.43
-0.19
-1.37
-0.88
-1.15
Basic EPS, GAAP
0.59
15.28
-16.95
-9.5
4.8
12.96
13.67
16.78
16.33
-6.1
13.88
-19.75
-75.66
-12.96
-12.68
-6.11
- -
Free Cash Flow per Basic Share
0.32
0.75
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
97.07
142.87
102.15
83.71
76.94
65.89
58.07
50.4
57.21
32.45
-37.34
143.12
137.73
137.48
136.29
136.3
- -
Book Value per Share
82.34
128.62
92.36
75.59
70.4
61.98
53.26
44.11
54.5
29.78
-39.82
140.87
133.49
131.6
129.39
127.99
- -
Tangible Book Value per Share
63
61
61
61
61
61
61
61
61
61
61
61
61
61
61
61
62
Basic Weighted Avg Shares
11,679
7,101
6,085
5,100
6,872
6,531
5,254
5,733
4,523
5,372
6,176
6,592
4,569
5,519
4,926
6,100
6,726
Sales/Revenue/Turnover
17.26
-21.96
-27.95
-29.61
4.14
8.65
6.48
7.16
-24.74
7.83
5.95
-7.86
-23.12
-8.01
-11.29
-5.36
-4.52
Operating Margin (%)
773
771
860
711
672
733
680
585
550
441
461
438
391
367
348
331
326
Depreciation Expense
1,447
-2,057
-2,343
-1,121
-1,065
-183
-562
-740
377
-1,943
-1,477
10,783
-332
-12
-84
-54
-71
Net Income, GAAP
13.14
- -
- -
- -
- -
- -
- -
- -
15.85
- -
- -
25.6
363.53
201.9
- -
- -
- -
Effective Tax Rate (%)
12.39
-28.96
-38.5
-21.99
-15.5
-2.8
-10.7
-12.9
8.34
-36.16
-23.91
163.57
-7.27
-0.21
-1.7
-0.88
-1.06
Profit Margin (%)
2,376
-150
-762
-4,540
-1,803
966
141
-1,307
-4,304
2,313
619
2,142
2,365
1,765
2,095
1,644
- -
Working Capital
4,237
5,125
6,899
5,832
7,230
7,857
7,141
5,707
461
6,131
7,351
341
202
150
150
150
- -
LT Debt
6,553
8,817
6,330
5,182
4,747
4,158
3,662
3,057
3,474
1,957
-2,317
8,737
8,401
8,382
8,306
8,289
- -
Total Equity
12.27
- -
- -
- -
- -
- -
- -
- -
12.57
- -
- -
162.16
0.5
1.63
- -
- -
- -
Return on Invested Capital (%)
13.52
- -
- -
- -
- -
- -
- -
- -
9.76
- -
- -
162.08
-4.84
-0.42
- -
- -
- -
Return on Capital (%)
21.44
-26.99
-31.22
-19.7
-21.65
-4.18
-14.8
-22.27
11.45
-70.75
- -
- -
-3.86
-0.14
-1
-0.64
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
150
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
61
61
Market Capitalization
23,049
18,133
34,659

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
5,130
- -
Cash, Cash Equivalents & STI
- -
1,269
- -
Accounts Receivable, Net
- -
735
- -
Inventories
- -
1,928
- -
Total Current Liabilities
- -
3,487
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-75.91%
-96.45%
-0.21%
Free Cash Flow
-53.53%
-19.22%
-51.86%
Net Income, GAAP
-100.29%
-90.37%
-35.76%
Sales/Revenue/Turnover
1.21%
1.98%
23.83%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1,157
1,474
1,635
1,325
4,926
2026
1,667
1,411
1,652
1,668
6,100
2027
1,996
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-2.59
0.77
0.74
-0.31
-1.37
2026
0.66
-2.27
0.65
0.08
-0.88
2027
0.38
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Panacea Biotec Limited engages in the research, development, manufacturing, and marketing of pharmaceuticals, vaccines, biosimilars, and nutraceuticals. Founded in 1984 and headquartered in New Delhi, India, with principal manufacturing facilities in Lalru, Punjab, and Baddi, Himachal Pradesh, the company operates globally across approximately 50 countries, targeting emerging and developing markets with affordable, high-quality products for public health initiatives and commercial segments. Its core offerings span multiple therapeutic categories including transplant drugs such as Tacrolimus (PanGraf), Mycophenolic acid (Mycept), and mycophenolate sodium (Mycept S); nephrology therapies like lanthanum carbonate, sevelamer, and valganciclovir; diabetes formulations including gliclazide (Glizid), metformin (Glizid M, Metlong), and glimepiride (Betaglim, Betaglim MR); gastroenterology and orthopaedics products such as Sitcom for haemorrhoids and aceclofenac combinations (Willgo CR); oncology treatments like protein-bound paclitaxel (PacliAll); and an extensive vaccine portfolio encompassing polio, Haemophilus influenzae type b, DPT combinations, hexavalent EasySix (DTwP-HepB-Hib-IPV), pentavalent EasyFive, pneumococcal, influenza, tetanus, and dengue vaccines, several of which hold WHO prequalification. Recent developments include securing a up to $20 million long-term loan from the US International Development Finance Corporation in September 2024 to expand manufacturing capacity for EasySix hexavalent vaccine antigens to meet UN agency demand; establishing Panacea Biotec Inc. as a wholly-owned step-down subsidiary in Delaware, USA, in June 2024 via an initial US$75,000 investment to penetrate the US healthcare market; and ongoing collaborations such as with Bionpharma Inc. and Rising Pharmaceuticals Inc. for distribution and production partnerships. The company maintains leadership in India's vaccines and formulations segments, supported by four state-of-the-art R&D centers employing over 300 scientists focused on novel drug delivery systems, new chemical and biological entities, and innovative vaccines.